BioSpace News Archive

Medifocus, Inc. announced it has commenced restructuring proceedings by filing for creditor protection to allow the Company to address the debt on its balance sheet.

Vertex Pharmaceuticals Incorporated (Canada) (Nasdaq: VRTX) today announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA), which represents an agreement in principle regarding the public reimbursement of PrTRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for eligible patients with cystic fibrosis (CF).

PerkinElmer, Inc. (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and reagents for a total consideration of approximately $5.25 billion.

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved CABOMETYX® (cabozantinib) for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are radioactive iodine-refractory or ineligible.

Astellas Pharma Inc. and Pfizer Inc. announced ahead of the European Society for Medical Oncology Congress 2021 that XTANDI® improved overall survival in the ARCHES study in men with metastatic hormone-sensitive prostate cancer.

Innovent Biologics, Inc. announced that the interim analysis results of the Phase 3 ORIENT-15 study evaluating sintilimab in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma were released in an oral presentation at the European Society for Medical Oncology Congress 2021.

VBL Therapeutics announced that the independent Data Safety Monitoring Committee of the ongoing OVAL Phase 3 registration-enabling study of VB-111 in ovarian cancer has conducted its fifth pre-planned review and has provided clearance to proceed with further clinical research as planned with no changes to the protocol.

Protagonist Therapeutics, Inc. announced the receipt of a verbal communication from the U.S. Food and Drug Administration that Protagonist’s clinical studies for rusfertide, an investigational product candidate currently in development, have been placed on a clinical hold.

Can-Fite BioPharma Ltd. announced its Vice President of Business of Development Dr. Sari Fishman will participate in three upcoming conferences to conduct meetings with potential development and commercialization partners for the Company’s portfolio of drug candidates.

Deciphera Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, announced four e-poster presentations at the ESMO Congress 2021.